Compass Pathways Plc
$ 5.53
-0.90%
10 Apr - close price
- Market Cap 712,946,000 USD
- Current Price $ 5.53
- High / Low $ 5.70 / 5.52
- Stock P/E N/A
- Book Value -0.55
- EPS -3.08
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.52 %
- ROE -5.65 %
- 52 Week High 8.90
- 52 Week Low 2.25
About
COMPASS Pathways plc is a mental health care company in the United Kingdom and the United States. The company is headquartered in Cheshire, the United Kingdom.
Analyst Target Price
$21.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-04 | 2025-07-30 | 2025-05-06 | 2025-02-26 | 2024-10-31 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-03 | 2023-05-11 |
| Reported EPS | -0.6065 | -1.44 | -0.4114 | -0.4185 | -0.63 | -0.56 | -0.56 | -0.55 | -0.53 | -0.67 | -0.62 | -0.57 |
| Estimated EPS | -0.3973 | -0.4 | -0.4228 | -0.49 | -0.63 | -0.57 | -0.52 | -0.49 | -0.33 | -0.43 | -0.69 | -0.68 |
| Surprise | -0.2092 | -1.04 | 0.0114 | 0.0715 | 0 | 0.01 | -0.04 | -0.06 | -0.2 | -0.24 | 0.07 | 0.11 |
| Surprise Percentage | -52.6554% | -260% | 2.6963% | 14.5918% | 0% | 1.7544% | -7.6923% | -12.2449% | -60.6061% | -55.814% | 10.1449% | 16.1765% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMPS
2026-04-08 11:10:12
Compass Pathways plc announced that its management will be attending the Needham Virtual Healthcare Conference on April 14, 2026, and will participate in a fireside chat. The company is a biotechnology firm focused on accelerating patient access to evidence-based innovation in mental health, particularly pioneering a new paradigm for treating mental health conditions. They are currently developing COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA for treatment-resistant depression.
2026-04-08 10:30:15
Compass Pathways plc announced that its management will attend the Needham Virtual Healthcare Conference on April 14, 2026. They will participate in a fireside chat at 12:45 pm ET, with a live audio webcast available on the Investors section of the company's website. Compass Pathways is a biotechnology company focused on mental health, developing investigational COMP360 synthetic psilocybin treatment for conditions like treatment-resistant depression.
2026-04-08 10:09:42
Compass Pathways plc announced that its management will attend the Needham Virtual Healthcare Conference on April 14, 2026, and participate in a fireside chat at 12:45 pm ET. A live audio webcast will be available on the "Events" page of their investor relations website, with a replay accessible for 30 days. The company, a biotechnology firm, focuses on developing evidence-based innovation for mental health, including its COMP360 synthetic psilocybin treatment for treatment-resistant depression.
2026-04-08 06:19:00
Compass Pathways plc, a biotechnology firm specializing in mental health treatments, has issued equity awards to seven new non-executive employees under its 2026 Inducement Plan. These grants, comprising options to purchase 117,445 shares and restricted share units or nominal cost options covering 55,875 shares, are designed to attract and retain top talent crucial for advancing its investigational COMP360 synthetic psilocybin treatment. The awards, approved by the company's Compensation and Leadership Development Committee, align with Nasdaq listing rules and vest over a four-year period.
2026-04-07 20:39:55
Compass Pathways plc announced it granted equity awards to seven newly hired non-executive employees under its 2026 Inducement Plan. These awards, consisting of options to purchase 117,445 shares and restricted share units/nominal cost options for 55,875 shares, were granted on April 1, 2026. The grants comply with NASDAQ Listing Rule 5635(c)(4) and serve as a material inducement for their employment.
2026-04-03 23:10:39
Compass Pathways has announced its seventh strategic collaboration, partnering with Radial Health, Inc. This collaboration aims to innovate the patient experience and inform the potential delivery model for COMP360 psilocybin treatment, if approved by the FDA. Radial Health, a national network of interventional psychiatry practices, will help Compass Pathways explore how this investigational treatment can seamlessly integrate into various healthcare settings.
